Conditional deletion of Rb causes early stage prostate cancer

Cancer Research

Volumn 64, Issue 17, 2004, Pages 6018-6025

  Maddison, Lisette A ^a,c   Sutherland, Brent W ^b   Barrios, Roberto J ^a   Greenberg, Norman M ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b USA   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER STAGING; CAUSE OF DEATH; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; GENE DELETION; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; GENE TARGETING; HETEROZYGOSITY LOSS; MALE; METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR SUPPRESSOR GENE;

ANIMALS; GENE DELETION; GENES, RETINOBLASTOMA; INTEGRASES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; NEOPLASM STAGING; PROSTATIC NEOPLASMS;

EID: 4344577121     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2509     Document Type: Article

References (51)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics. CA Cancer J Clin 2004;54:8-29.
2. He WW, Sciavolino PJ, Wing J, et al. A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics 1997;43:69-77.
3. Voeller HJ, Augustus M, Madike V, Bova, GS, Carter KC, Gelmann EP. Coding region of NKX3.1, a prostate-specific homeobox gene on 8p21, is not mutated in human prostate cancers. Cancer Res 1997;57:4455-9. Erratum in: Cancer Res 1997;57:5613.
4. Voeller HJ, Augustus M, Madike V, Bova, GS, Carter KC, Gelmann EP. Coding region of NKX3.1, a prostate-specific homeobox gene on 8p21, is not mutated in human prostate cancers. Cancer Res 1997;57:4455-9. Erratum in: Cancer Res 1997;57:5613.
5. Feilotter HE, Nagai MA, Boag AH, Eng C, Mulligan LM. Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene 1998;16:1743-8.
6. Li C, Larsson C, Futreal A, et al. Identification of two distinct deleted regions on chromosome 13 in prostate cancer. Oncogene 1998;16:481-7.
7. Dong JT, Boyd JC, Frierson HF Jr. Loss of heterozygosity at 13q 14 and 13q21 in high grade, high stage prostate cancer. Prostate 2001;49:166-71.
8. Alers JC, Krijtenburg PJ, Vis AN, et al. Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies: early cancers may contain aggressive genetic features. Am J Pathol 2001;158:399-406.
9. Massenkeil G, Oberhuber H, Hailemariam S, et al. P53 mutations and loss of heterozygosity on chromosomes 8p, 16q, 17p, and 18q are confined to advanced prostate cancer. Anticancer Res 1994;14:2785-90.
10. Saric T, Brkanac Z, Troyer DA, et al. Genetic pattern of prostate cancer progression. Int J Cancer 1999;81:219-24.
11. Bhatia GR, Donjacour A, Sciavolino P, et al. Roles for Nkx3.1 in prostate development and cancer. Genes Dev 1999;13:966-77.
12. Wang SI, Parsons R, Ittmann M. Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. Clin Cancer Res 1998;4:811-5.
13. Henke RP, Kruger E, Ayhan N, Hubner D, Hammerer P, Huland H. Immunohistochemical detection of p53 protein in human prostatic cancer. J Urol 1994;152:1297-301.
14. Voeller HJ, Sugars LY, Pretlow T, Gelmann EP. p53 oncogene mutations in human prostate cancer specimens. J Urol 1994;151:492-5.
15. Bookstein R, Rio P, Madreperla SA, et al. Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci USA 1990;87:7762-6.
16. Phillips SMA, Barton CM, Lee SJ, et al. Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. Br J Cancer 1994;70:1252-7.
17. Melamed J, Einhorn JM, Ittmann MM. Allelic loss on chromosome 13q in human prostate carcinoma. Clin Cancer Res 1997;3:1867-72.
18. Ittmann MM, Wieczorek R. Alterations of the retinoblstoma gene in clinically localized, stage B prostate adenocarcinomas. Hum Pathol 1996;27:28-34.
19. Tricoli JV, Gumerlock PH, Yao JL, et al. The Cooperative Prostate Network, N. C. I. Alterations of the retinoblastoma gene in human prostate adenocarcinoma. Genes, Chromosomes & Cancer 1996;15:108-14.
20. Brooks JD, Bova GS, Isaacs WB. Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas. The Prostate 1995;26:35-9.
21. Phillips SMA, Morton DG, Lee SJ, Wallace DMA, Neoptolemos JP. Loss of heterozygosity of the retinoblastoma and adenomatous polyposis susceptibility gene loci and in chromosomes 10p, 10q and 16q in human prostate cancer. Br J Urol 1994;73.
22. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev 1998;12:2245-62.
23. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
24. Drobnjak M, Osman I, Scher HI, Fazzari M, Cordon-Cardo C. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res 2000;6:1891-5.
25. Gumbiner LM, Gumerlock PH, Mack PC, et al. Overexpression of cyclin D1 is rare in human prostate carcinoma. Prostate 1999;38:40-5.
26. Henshall SM, Quinn DI, Lee CS, et al. Overexpression of the cell cycle inhibitor p16INK4A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients. Clin Cancer Res 2001;7:544-50.
27. Lee CT, Capodieci P, Osman I, et al. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer. Clin Cancer Res 1999;5:977-83.
28. Gingrich J, Barrios R, Foster B, Greenberg N. Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer and Prostatic Diseases 1999;2:70-5.
29. Maroulakou I, Anver M, Garrett L, Green J. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc Natl Acad Sci USA 1994;91:11236-40.
30. Kasper S, Sheppard PC, Yan Y, et al. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer [corrected and republished article originally printed in Lab Investig 1998;Mar 78(3):319-33]. Lab Investig 1998;78:i-xv.
31. Kasper S, Sheppard PC, Yan Y, et al. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer [corrected and republished article originally printed in Lab Investig 1998;Mar 78(3):319-33]. Lab Investig 1998;78:i-xv.
32. Clarke AR, Maandag ER, van Roon M, et al. Requirement for a functional Rb-1 gene in murine development. Nature 1992;359:328-30.
33. Lee EYP, Chang C, Hu N, et al. Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature 1992;359:288-94.
34. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA. Effects of an Rb mutation in the mouse. Nature 1992;359:295-300.
35. Wang Y, Hayward SW, Donjacour AA, et al. Sex hormone-induced carcinogenesis in Rb-deficient prostate tissue. Cancer Res 2000;60:6008-17.
36. Nagy A. Cre recombinase: the universal reagent for genome tailoring. Genesis 2000;26:99-109.
37. Vooijs M, van der Valk M, te Riele H, Berns A. Flp-mediated tissue-specific inactivation of the retinblastoma tumor suppressor gene in the mouse. Oncogene 1998;17:1-12.
38. Marino S, Vooijs M, van Der Gulden H, Jonkers J, Berns A. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev 2000;14:994-1004.
39. Maddison L, Nahm H, DeMayo F, Greenberg N. Prostate specific expression of Cre recombinase in transgenic mice. Genesis 2000;26:154-6.
40. Huss WJ, Hanrahan CF, Barrios RJ, Simons JW, Greenberg NM. Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res 2001;61:2736-43.
41. Park JH, Walls JE, Galvez JJ, et al. Prostatic intraepithelial neoplasia in genetically engineered mice. Am J Pathol 2002;161:727-35.
42. Trotman LC, Niki M, Dotan ZA, et al. Pten Dose Dictates Cancer Progression in the Prostate. PLoS Biol 2003;1:E59.
43. Day KC, McCabe MT, Zhao X, et al. Rescue of embryonic epithelium reveals that the homozygous deletion of the retinoblastoma gene confers growth factor independence and immortality but does not influence epithelial differentiation or tissue morphogenesis. J Biol Chem 2002;277:44475-84.
44. Podsypanina K, Ellenson LH, Nemes A, et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 1999;96:1563-8.
45. Cordon-Cardo C, Koff A, Drobnjak M, et al. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma [see comments]. J Natl Cancer Inst 1998;90:1284-91.
46. Abdulkadir SA, Magee JA, Peters TJ, et al. Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol Cell Biol 2002;22:1495-503.
47. Wu J, Wu X, Huang J, Powell WC, Matusik RJ, Roy-Burman P. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. In: AACR: Mouse Models of Cancer, La Jolla, California;2000;A-27.
48. Stanbrough M, Leav I, Kwan PW, Bubley GJ, Balk SP. Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. Proc Natl Acad Sci USA 2001;98:10823-8.
49. Classon M, Dyson N. p107 and p 130: versatile proteins with interesting pockets. Exp Cell Res 2001;264:135-47.
50. Claudio PP, Zamparelli A, Garcia FU, et al. Expression of Cell-Cycle-regulated Proteins pRb2/p130, p107, p27(kip1), p53, mdm-2, and Ki-67 (MIB-1) in Prostatic Gland Adenocarcinoma. Clin Cancer Res 2002;8:1808-15.
51. Bates S, Phillips AC, Clark PA, et al. p14ARF links the tumour suppressors RB and p53. Nature 1998;395:124-5.